Tác động của virus coronavirus mới và việc tiêm phòng đến hội chứng Guillain–Barré là gì?

Dalakas MC (2020) Guillain-Barré syndrome: the first documented COVID-19-triggered autoimmune neurologic disease: More to come with myositis in the offing. Neurol Neuroimmunol Neuroinflamm 7(5) Willison HJ, Jacobs BC, van Doorn PA (2016) Guillain-Barré syndrome. Lancet 388(10045):717–727 Lapostolle F, Schneider E, Vianu I et al (2020) Clinical features of 1487 COVID-19 patients with outpatient management in the Greater Paris: the COVID-call study. Intern Emerg Med 15(5):813–817 Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E et al (2020) Neurologic manifestations in hospitalized patients with COVID-19: the ALBACOVID registry. Neurology 95(8):e1060–e1070 Lechien JR, Chiesa-Estomba CM, Place S et al (2020) Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. J Intern Med 288(3):335–344 Khedr EM, Abo-Elfetoh N, Deaf E et al (2021) Surveillance study of acute neurological manifestations among 439 Egyptian patients with COVID-19 in Assiut and Aswan university hospitals. Neuroepidemiology 55(2):109–118 Mao L, Jin H, Wang M et al (2020) Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan. China JAMA Neurol 77(6):683–690 Filosto M, CottiPiccinelli S, Gazzina S et al (2021) Guillain-Barré syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions. J Neurol Neurosurg Psychiatry 92(7):751–756 Xu E, Xie Y, Al-Aly Z (2022) Long-term neurologic outcomes of COVID-19. Nat Med. https://doi.org/10.1038/s41591-022-02001-z Kevadiya BD, Machhi J, Herskovitz J et al (2021) Diagnostics for SARS-CoV-2 infections. Nat Mater 20(5):593–605 Patone M, Handunnetthi L, Saatci D et al (2021) Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat Med 27(12):2144–2153 Ray STJ, Abdel-Mannan O, Sa M et al (2021) Neurological manifestations of SARS-CoV-2 infection in hospitalised children and adolescents in the UK: a prospective national cohort study. Lancet Child Adolesc Health 5(9):631–641 LaRovere KL, Riggs BJ, Poussaint TY et al (2021) Neurologic involvement in children and adolescents hospitalized in the United States for COVID-19 or multisystem inflammatory syndrome. JAMA Neurol 78(5):536–547 Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y (2021) The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev 20(4):102792 Khan F, Sharma P, Pandey S et al (2021) COVID-19-associated Guillain-Barre syndrome: postinfectious alone or neuroinvasive too? J Med Virol 93(10):6045–6049 Zhao H, Shen D, Zhou H, Liu J, Chen S (2020) Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol 19(5):383–384 Finsterer J, Scorza FA (2021) Guillain-Barre syndrome in 220 patients with COVID-19. Egypt J Neurol Psychiatr Neurosurg 57(1):55 Abu-Rumeileh S, Abdelhak A, Foschi M, Tumani H, Otto M (2021) Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol 268(4):1133–1170 Uncini A, Vallat JM, Jacobs BC (2020) Guillain-Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic. J Neurol Neurosurg Psychiatry 91(10):1105–1110 Carrillo-Larco RM, Altez-Fernandez C, Ravaglia S, Vizcarra JA (2020) COVID-19 and Guillain-Barre Syndrome: a systematic review of case reports. Wellcome Open Res 5:107 Manganotti P, Bellavita G, D’Acunto L et al (2021) Clinical neurophysiology and cerebrospinal liquor analysis to detect Guillain-Barré syndrome and polyneuritis cranialis in COVID-19 patients: a case series. J Med Virol 93(2):766–774 Fredrich S, Greenberg BM, Hatanpaa KJ (2021) Neurological infections in 2020: COVID-19 takes centre stage. Lancet Neurol 20(1):17–18 Rosenblum HG, Hadler SC, Moulia D et al (2021) Use of COVID-19 vaccines after reports of adverse events among adult recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna): update from the Advisory Committee on Immunization Practices - United States, July 2021. MMWR Morb Mortal Wkly Rep 70(32):1094–1099 David SS, Potasman I, Rahamim-Cohen D (2021) Rate of recurrent Guillain-Barré syndrome after mRNA COVID-19 vaccine BNT162b2. JAMA Neurol 78(11):1409–1411 Woo EJ, Mba-Jonas A, Dimova RB, Alimchandani M, Zinderman CE, Nair N (2021) Association of receipt of the Ad26.COV2S COVID-19 vaccine with presumptive Guillain-Barré syndrome, February-July 2021. Jama 326(16):1606–1613 Li X, Raventós B, Roel E et al (2022) Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis. BMJ 376:e068373 Rodríguez Y, Rojas M, Beltrán S et al (2022) Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review. J Autoimmun 132:102898 Allen CM, Ramsamy S, Tarr AW et al (2021) Guillain-Barré syndrome variant occurring after SARS-CoV-2 vaccination. Ann Neurol 90(2):315–318 van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA (2014) Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol 10(8):469–482 Shui IM, Rett MD, Weintraub E et al (2012) Guillain-Barré syndrome incidence in a large United States cohort (2000–2009). Neuroepidemiology 39(2):109–115 Sejvar JJ, Baughman AL, Wise M, Morgan OW (2011) Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology 36(2):123–133 Yuki N, Hartung HP (2012) Guillain-Barré syndrome. N Engl J Med 366(24):2294–2304 Vakili K, Fathi M, Hajiesmaeili M et al (2021) Neurological symptoms, comorbidities, and complications of COVID-19: a literature review and meta-analysis of observational studies. Eur Neurol 84(5):307–324 Mussinatto I, Benevenuta C, Caci A et al (2022) Possible association between Guillain-Barré syndrome and SARS-CoV-2 infection in children: a case report and literature review. Exp Ther Med 24(1):462 Rahimi K (2020) Guillain-Barre syndrome during COVID-19 pandemic: an overview of the reports. Neurol Sci 41(11):3149–3156 Paliwal VK, Garg RK, Gupta A, Tejan N (2020) Neuromuscular presentations in patients with COVID-19. Neurol Sci 41(11):3039–3056 Shao SC, Wang CH, Chang KC, Hung MJ, Chen HY, Liao SC (2021) Guillain-Barré syndrome associated with COVID-19 vaccination. Emerg Infect Dis 27(12):3175–3178 Keddie S, Pakpoor J, Mousele C et al (2021) Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome. Brain 144(2):682–693 Taga A, Lauria G (2022) COVID-19 and the peripheral nervous system. A 2-year review from the pandemic to the vaccine era. J Peripher Nerv Syst 27(1):4–30 Hanson KE, Goddard K, Lewis N et al (2022) Incidence of Guillain-Barré syndrome after COVID-19 vaccination in the vaccine safety datalink. JAMA Netw Open 5(4):e228879 how-its-designed.; Available from: https://www.janssencovid19vaccine.com/hcp/how-its-designed.html Rashedi R, Samieefar N, Masoumi N, Mohseni S, Rezaei N (2022) COVID-19 vaccines mix-and-match: the concept, the efficacy and the doubts. J Med Virol 94(4):1294–1299 Oo WM, Giri P, de Souza A (2021) AstraZeneca COVID-19 vaccine and Guillain- Barré Syndrome in Tasmania: a causal link? J Neuroimmunol 360:577719 Frontera JA, Tamborska AA, Doheim MF et al (2022) Neurological events reported after COVID-19 vaccines: an analysis of VAERS. Ann Neurol 91(6):756–771 Bellucci M, Germano F, Grisanti S et al (2022) Case report: Post-COVID-19 vaccine recurrence of Guillain-Barré syndrome following an antecedent parainfectious COVID-19-related GBS. Front Immunol 13:894872 United States Department of Health and Human Services (DHHS), PHSP, Centers for Disease Control (CDC) / Food and Drug Administration (FDA), Vaccine Adverse Event Reporting System (VAERS). CDC WONDER On-line Database. 1990 - 09/16/2022; Available from: http://wonder.cdc.gov/vaers.html Li X, Ostropolets A, Makadia R et al (2021) Characterising the background incidence rates of adverse events of special interest for COVID-19 vaccines in eight countries: multinational network cohort study. BMJ 373:n1435 Li C, Lee A, Grigoryan L et al (2022) Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine. Nat Immunol 23(4):543–555 Karikó K, Muramatsu H, Welsh FA et al (2008) Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther 16(11):1833–1840 Klein NP, Lewis N, Goddard K et al (2021) Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA 326(14):1390–1399 Mahroum N, Lavine N, Ohayon A et al (2022) COVID-19 vaccination and the rate of immune and autoimmune adverse events following immunization: insights from a narrative literature review. Front Immunol 13:872683 Finsterer J, Scorza FA, Scorza CA (2021) Post SARS-CoV-2 vaccination Guillain-Barre syndrome in 19 patients. Clinics (Sao Paulo) 76:e3286 Takahashi K, Tomoda Y, Kadena S, Kanbayashi T, Kobayashi S, Kato R (2022) Guillain-Barré syndrome after BNT162b2 (Pfizer-BioNTec) vaccination. QJM 115(5):331–333 Voysey M, Clemens SAC, Madhi SA et al (2021) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397(10269):99–111 European Medicines agency (EMA). Available from: https://www.ema.europa.eu/en Agency EM (2021) Meeting Highlights From the Pharmacovigilance Risk Assessment Committee (PRAC). Available at:. Available from: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-5-8-july-2021 Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC (2014) Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain 137(Pt 1):33–43 Iadecola C, Anrather J, Kamel H (2020) Effects of COVID-19 on the nervous system. Cell 183(1):16-27.e1 Karimi N, Boostani R, Fatehi F et al (2021) Guillain-Barre syndrome and COVID-19 vaccine: a report of nine patients. Basic Clin Neurosci 12(5):703–710 Tabatabaee S, Rezania F, Alwedaie SMJ et al (2022) Post COVID-19 vaccination Guillain-Barre syndrome: three cases. Hum Vaccin Immunother 18(5):2045153 Nelson KE (2012) Invited commentary: Influenza vaccine and Guillain-Barre syndrome–is there a risk? Am J Epidemiol 175(11):1129–1132 Goodman JL, Grabenstein JD, Braun MM (2020) Answering key questions about COVID-19 vaccines. JAMA 324(20):2027–2028 Márquez Loza AM, Holroyd KB, Johnson SA, Pilgrim DM, Amato AA (2021) Guillain- Barré Syndrome in the Placebo and Active Arms of a COVID-19 Vaccine Clinical Trial: Temporal Associations Do Not Imply Causality. Neurology. https://doi.org/10.1212/wnl.0000000000011881 McKean N, Chircop C (2021) Guillain-Barré syndrome after COVID-19 vaccination. BMJ Case Rep 14(7). https://doi.org/10.1136/bcr-2021-244125 Administration FAD (2021) Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration. Janssen COVID-19 vaccine emergency use authorization. Available from: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/Janssen-covid-19-vaccine Ling L, Bagshaw SM, Villeneuve PM (2021) Guillain-Barré syndrome after SARS-CoV-2 vaccination in a patient with previous vaccine-associated Guillain-Barré syndrome. CMAJ 193(46):E1766-e1769 Rajabally YA, Durand MC, Mitchell J, Orlikowski D, Nicolas G (2015) Electrophysiological diagnosis of Guillain-Barré syndrome subtype: could a single study suffice? J Neurol Neurosurg Psychiatry 86(1):115–119 Elzouki AN, Osman MAM, Ahmed MAE et al (2021) COVID-19 infection presented as Guillain-Barre Syndrome: report of two new cases and review of 116 reported cases and case series. Travel Med Infect Dis 44:102169 Uncini A, Foresti C, Frigeni B et al (2021) Electrophysiological features of acute inflammatory demyelinating polyneuropathy associated with SARS-CoV-2 infection. Neurophysiol Clin 51(2):183–191 Wijdicks EF, Klein CJ (2017) Guillain-Barré Syndrome. Mayo Clin Proc 92(3):467–479 Galassi G, Marchioni A (2022) Acute neuromuscular syndromes with respiratory failure during COVID-19 pandemic: where we stand and challenges ahead. J Clin Neurosci 101:264–275 Toscano G, Palmerini F, Ravaglia S et al (2020) Guillain-Barré syndrome associated with SARS-CoV-2. N Engl J Med 382(26):2574–2576 Sansone P, Giaccari LG, Aurilio C, Coppolino F, Esposito V, Fiore M, Paladini A, Passavanti MB, Pota V, Pace MC (2021) Post-Infectious Guillain-Barré Syndrome Related to SARS-CoV-2 Infection: A Systematic Review. Life (Basel) 11(2). https://doi.org/10.3390/life11020167 Herman C, Mayer K, Sarwal A (2020) Scoping review of prevalence of neurologic comorbidities in patients hospitalized for COVID-19. Neurology 95(2):77–84 Fragiel M, Miró Ò, Llorens P et al (2021) Incidence, clinical, risk factors and outcomes of Guillain-Barré in Covid-19. Ann Neurol 89(3):598–603 Caress JB, Castoro RJ, Simmons Z et al (2020) COVID-19-associated Guillain-Barré syndrome: the early pandemic experience. Muscle Nerve 62(4):485–491 Gupta A, Paliwal VK, Garg RK (2020) Is COVID-19-related Guillain-Barré syndrome different? Brain Behav Immun 87:177–178 Raphaël JC, Chevret S, Hughes RA, Annane D (2012) Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev 7:Cd001798 Hughes RA, Swan AV, van Doorn PA (2014) Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2014(9):Cd002063 Hasan I, Saif-Ur-Rahman KM, Hayat S et al (2020) Guillain-Barré syndrome associated with SARS-CoV-2 infection: a systematic review and individual participant data meta-analysis. J Peripher Nerv Syst 25(4):335–343 Schweitzer F, Kleineberg NN, Göreci Y, Onur OA, Franke C, Warnke C (2021) Neuro-COVID-19 is more than anosmia: clinical presentation, neurodiagnostics, therapies, and prognosis. Curr Opin Neurol 34(3):423–431